一线伊布替尼治疗伴TP53异常慢性淋巴细胞白血病患者的长期疗效:四项临床试验的汇总分析
本汇总分析纳入四项研究(PCYC-1122e、RESONATE-2、iLLUMINATE、ECOG-ACRIN E1912)中89例伴TP53异常的初治慢性淋巴细胞白血病患者,接受单药伊布替尼(n=45)或伊布替尼联合抗CD20抗体(n=44)治疗。中位随访49.8个月时中位无进展生存期未达到,4年无进展生存率和总生存率估计分别为79%和88%,总缓解率93%(完全缓解39%),未发现新的安全性信号。
要点
- 中位随访49.8个月,伴TP53异常初治CLL患者一线伊布替尼治疗后中位无进展生存期未达到。
- 4年无进展生存率79%、总生存率88%,总缓解率93%,完全缓解39%。
- 分析未发现新的安全性信号,末次随访时46%患者仍在接受伊布替尼治疗。
核心结论
- 中位随访约四年(最长八年)的汇总数据提示,一线伊布替尼为基础治疗在伴TP53异常的CLL患者中似有良好的长期结局。
研究设计与样本
- 四项研究(PCYC-1122e、RESONATE-2、iLLUMINATE、ECOG-ACRIN E1912)的汇总分析,共纳入89例伴TP53异常的初治CLL患者。
- 单药伊布替尼组45例,伊布替尼联合抗CD20抗体组44例;全部89例均携带del(17p)(占89例的53%)和/或TP53突变(58例有TP53测序结果者中占91%)。
主要发现
- 中位随访49.8个月(范围0.1-95.9个月),中位无进展生存期未达到,4年无进展生存率估计79%、总生存率估计88%。
- 总缓解率93%,其中完全缓解占39%;末次随访时46%患者仍在接受伊布替尼治疗。
- 本分析未发现新的安全性信号。
关键数值与推荐
- 4年无进展生存率估计为79%,4年总生存率估计为88%。
- 总缓解率93%,完全缓解率39%。
- 中位随访49.8个月(范围0.1-95.9个月)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
TP53 aberrations [del(17p) or TP53 mutation] predict poor survival with chemoimmunotherapy in patients with chronic lymphocytic leukaemia (CLL). We evaluated long-term efficacy and safety of first-line ibrutinib-based therapy in patients with CLL bearing TP53 aberrations in a pooled analysis across four studies: PCYC-1122e, RESONATE-2 (PCYC-1115/16), iLLUMINATE (PCYC-1130) and ECOG-ACRIN E1912. The pooled analysis included 89 patients with TP53 aberrations receiving first-line treatment with single-agent ibrutinib (n = 45) or ibrutinib in combination with an anti-CD20 antibody (n = 44). All 89 patients had del(17p) (53% of 89 patients) and/or TP53 mutation (91% of 58 patients with TP53 sequencing results available). With a median follow-up of 49·8 months (range, 0·1-95·9), median progression-free survival was not reached. Progression-free survival rate and overall survival rate estimates at four years were 79% and 88%, respectively. Overall response rate was 93%, including complete response in 39% of patients. No new safety signals were identified in this analysis. Forty-six percent of patients remained on ibrutinib treatment at last follow-up. With median follow-up of four years (up to eight years), results from this large, pooled, multi-study data set suggest promising long-term outcomes of first-line ibrutinib-based therapy in patients with TP53 aberrations. Registered at ClinicalTrials.gov (NCT01500733, NCT01722487, NCT02264574 and NCT02048813).
引用
- Allan JN, Shanafelt T, Wiestner A, et al. Long-term efficacy of first-line ibrutinib treatment for chronic lymphocytic leukaemia in patients with TP53 aberrations: a pooled analysis from four clinical trials. Br J Haematol. 2021. PMID: 34865212. doi:10.1111/bjh.17984
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。